GlassScriptPhysician profile
Manuela M Mendes
NPI 1912904988
$13,343.49
in general payments reported to CMS, 2019-2025
64 companies · $2,340 in 2025
The $2,340 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,165 · 2020: $549 · 2021: $1,433 · 2022: $2,077 · 2023: $2,452 · 2024: $2,327 · 2025: $2,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,099 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,098.59 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,585.08 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,393.44 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $957.70 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $686.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $633.65 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $548.56 | 2019-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $477.95 | 2019-2025 | Eliquis, Camzyos |
| Lilly USA, LLC | $464.51 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $463.61 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $452.99 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $442.04 | 2019-2023 | Xarelto |
| Ardelyx, INC. | $441.53 | 2023-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $402.90 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $367.04 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.71 | 2019-2025 | Jardiance, Spiriva Respimat, Combivent Respimat |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuela Mendes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.